Effect of the rs2259816 polymorphism in the HNF1A gene on circulating levels of c-reactive protein and coronary artery disease (the ludwigshafen risk and cardiovascular health study)

BMC Medical Genetics

Volumn 11, Issue 1, 2010, Pages

  Kleber, Marcus E ^a   Grammer, Tanja B ^b   Renner, Wilfried ^c   März, Winfried ^b,d  

^a LURIC Study Nonprofit LLC   (Germany)

^b SYNLAB ACADEMY   (Germany)

^c MEDICAL UNIVERSITY OF GRAZ   (Austria)

^d UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; C REACTIVE PROTEIN; GENOMIC DNA; GLUCOSE; HEPATOCYTE NUCLEAR FACTOR 1ALPHA; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; HNF1A PROTEIN, HUMAN;

ACUTE HEART INFARCTION; ADULT; AGED; ALLELE; ANGIOCARDIOGRAPHY; ARTICLE; BODY MASS; CARDIOVASCULAR RISK; CIRCULATION; COHORT ANALYSIS; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY ARTERY OBSTRUCTION; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; FEMALE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC RISK; GENOTYPE; GLUCOSE BLOOD LEVEL; HEART MUSCLE ISCHEMIA; HETEROZYGOTE; HOMOZYGOTE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; RISK ASSESSMENT; SMOKING; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; SYSTOLIC BLOOD PRESSURE; BLOOD; GENETICS; GERMANY; METABOLISM; RISK FACTOR;

C-REACTIVE PROTEIN; COHORT STUDIES; CORONARY ARTERY DISEASE; GENOTYPE; GERMANY; HEPATOCYTE NUCLEAR FACTOR 1-ALPHA; HUMANS; POLYMORPHISM, GENETIC; RISK FACTORS;

EID: 78049501826     PISSN: None     EISSN: 14712350     Source Type: Journal    
DOI: 10.1186/1471-2350-11-157     Document Type: Article

References (49)

1. Danesh J, Whincup P, Walker M, Lennon L, Thomson A, Appleby P, Gallimore JR, Pepys MB. Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses. BMJ 2000, 321(7255):199-204. 10.1136/bmj.321.7255.199, 27435, 10903648.
2. Ridker PM, Bassuk SS, Toth PP. C-reactive protein and risk of cardiovascular disease: evidence and clinical application. Curr Atheroscler Rep 2003, 5(5):341-349. 10.1007/s11883-003-0004-3, 12911843.
3. Ridker PM. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation 2003, 107(3):363-369. 10.1161/01.CIR.0000053730.47739.3C, 12551853.
4. Hingorani AD, Shah T, Casas JP, Humphries SE, Talmud PJ. C-reactive protein and coronary heart disease: predictive test or therapeutic target?. Clin Chem 2009, 55(2):239-255. 10.1373/clinchem.2008.115923, 19114670.
5. Schunkert H, Samani NJ. Elevated C-reactive protein in atherosclerosis--chicken or egg?. N Engl J Med 2008, 359(18):1953-1955. 10.1056/NEJMe0807235, 18971498.
6. Casas JP, Shah T, Hingorani AD, Danesh J, Pepys MB. C-reactive protein and coronary heart disease: a critical review. J Intern Med 2008, 264(4):295-314. 10.1111/j.1365-2796.2008.02015.x, 18823504.
7. Casas JP, Shah T, Cooper J, Hawe E, McMahon AD, Gaffney D, Packard CJ, O'Reilly DS, Juhan-Vague I, Yudkin JS, Tremoli E, Margaglione M, Di Minno G, Hamsten A, Kooistra T, Stephens JW, Hurel SJ, Livingstone S, Colhoun HM, Miller GJ, Bautista LE, Meade T, Sattar N, Humphries SE, Hingorani AD. Insight into the nature of the CRP-coronary event association using Mendelian randomization. Int J Epidemiol 2006, 35(4):922-931. 10.1093/ije/dyl041, 16565153.
8. Zee RY, Ridker PM. Polymorphism in the human C-reactive protein (CRP) gene, plasma concentrations of CRP, and the risk of future arterial thrombosis. Atherosclerosis 2002, 162(1):217-219. 10.1016/S0021-9150(01)00703-1, 11947917.
9. Miller DT, Zee RY, Suk Danik J, Kozlowski P, Chasman DI, Lazarus R, Cook NR, Ridker PM, Kwiatkowski DJ. Association of common CRP gene variants with CRP levels and cardiovascular events. Ann Hum Genet 2005, 69(Pt 6):623-638. 10.1111/j.1529-8817.2005.00210.x, 16266402.
10. Kardys I, de Maat MP, Uitterlinden AG, Hofman A, Witteman JC. C-reactive protein gene haplotypes and risk of coronary heart disease: the Rotterdam Study. Eur Heart J 2006, 27(11):1331-1337. 10.1093/eurheartj/ehl018, 16682383.
11. Zhang L, Kao WH, Berthier-Schaad Y, Plantinga L, Fink N, Smith MW, Coresh J. C-Reactive protein haplotype predicts serum C-reactive protein levels but not cardiovascular disease risk in a dialysis cohort. Am J Kidney Dis 2007, 49(1):118-126. 10.1053/j.ajkd.2006.10.008, 17185152.
12. Grammer TB, Marz W, Renner W, Bohm BO, Hoffmann MM. C-reactive protein genotypes associated with circulating C-reactive protein but not with angiographic coronary artery disease: the LURIC study. Eur Heart J 2009, 30(2):170-182. 10.1093/eurheartj/ehn191, 18499652.
13. Zacho J, Tybjaerg-Hansen A, Jensen JS, Grande P, Sillesen H, Nordestgaard BG. Genetically elevated C-reactive protein and ischemic vascular disease. N Engl J Med 2008, 359(18):1897-1908. 10.1056/NEJMoa0707402, 18971492.
14. Crawford DC, Sanders CL, Qin X, Smith JD, Shephard C, Wong M, Witrak L, Rieder MJ, Nickerson DA. Genetic variation is associated with C-reactive protein levels in the Third National Health and Nutrition Examination Survey. Circulation 2006, 114(23):2458-2465. 10.1161/CIRCULATIONAHA.106.615740, 17101857.
15. Lange LA, Carlson CS, Hindorff LA, Lange EM, Walston J, Durda JP, Cushman M, Bis JC, Zeng D, Lin D, Kuller LH, Nickerson DA, Psaty BM, Tracy RP, Reiner AP. Association of polymorphisms in the CRP gene with circulating C-reactive protein levels and cardiovascular events. JAMA 2006, 296(22):2703-2711. 10.1001/jama.296.22.2703, 17164456.
16. Jylhava J, Eklund C, Pessi T, Raitakari OT, Juonala M, Kahonen M, Viikari JS, Lehtimaki T, Hurme M. Genetics of C-reactive protein and complement factor H have an epistatic effect on carotid artery compliance: the Cardiovascular Risk in Young Finns Study. Clin Exp Immunol 2009, 155(1):53-58. 10.1111/j.1365-2249.2008.03752.x, 2665679, 19076828.
17. Kaptoge S, Di Angelantonio E, Lowe G, Pepys MB, Thompson SG, Collins R, Danesh J. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet 375(9709):132-140.
18. Pankow JS, Folsom AR, Cushman M, Borecki IB, Hopkins PN, Eckfeldt JH, Tracy RP. Familial and genetic determinants of systemic markers of inflammation: the NHLBI family heart study. Atherosclerosis 2001, 154(3):681-689. 10.1016/S0021-9150(00)00586-4, 11257270.
19. Retterstol L, Eikvar L, Berg K. A twin study of C-Reactive Protein compared to other risk factors for coronary heart disease. Atherosclerosis 2003, 169(2):279-282. 10.1016/S0021-9150(03)00192-8, 12921979.
20. MacGregor AJ, Gallimore JR, Spector TD, Pepys MB. Genetic effects on baseline values of C-reactive protein and serum amyloid a protein: a comparison of monozygotic and dizygotic twins. Clin Chem 2004, 50(1):130-134. 10.1373/clinchem.2003.028258, 14633907.
21. Szalai AJ, McCrory MA, Cooper GS, Wu J, Kimberly RP. Association between baseline levels of C-reactive protein (CRP) and a dinucleotide repeat polymorphism in the intron of the CRP gene. Genes Immun 2002, 3(1):14-19. 10.1038/sj.gene.6363820, 11857055.
22. Brull DJ, Serrano N, Zito F, Jones L, Montgomery HE, Rumley A, Sharma P, Lowe GD, World MJ, Humphries SE, Hingorani AD. Human CRP gene polymorphism influences CRP levels: implications for the prediction and pathogenesis of coronary heart disease. Arterioscler Thromb Vasc Biol 2003, 23(11):2063-2069. 10.1161/01.ATV.0000084640.21712.9C, 12842840.
23. Wolford JK, Gruber JD, Ossowski VM, Vozarova B, Antonio Tataranni P, Bogardus C, Hanson RL. A C-reactive protein promoter polymorphism is associated with type 2 diabetes mellitus in Pima Indians. Mol Genet Metab 2003, 78(2):136-144. 10.1016/S1096-7192(02)00230-5, 12618085.
24. Russell AI, Cunninghame Graham DS, Shepherd C, Roberton CA, Whittaker J, Meeks J, Powell RJ, Isenberg DA, Walport MJ, Vyse TJ. Polymorphism at the C-reactive protein locus influences gene expression and predisposes to systemic lupus erythematosus. Hum Mol Genet 2004, 13(1):137-147. 10.1093/hmg/ddh021, 14645206.
25. Obisesan TO, Leeuwenburgh C, Phillips T, Ferrell RE, Phares DA, Prior SJ, Hagberg JM. C-reactive protein genotypes affect baseline, but not exercise training-induced changes, in C-reactive protein levels. Arterioscler Thromb Vasc Biol 2004, 24(10):1874-1879. 10.1161/01.ATV.0000140060.13203.22, 2643022, 15271790.
26. de Maat MP, Bladbjerg EM, Hjelmborg JB, Bathum L, Jespersen J, Christensen K. Genetic influence on inflammation variables in the elderly. Arterioscler Thromb Vasc Biol 2004, 24(11):2168-2173. 10.1161/01.ATV.0000143856.01669.e7, 15345506.
27. Kovacs A, Green F, Hansson LO, Lundman P, Samnegard A, Boquist S, Ericsson CG, Watkins H, Hamsten A, Tornvall P. A novel common single nucleotide polymorphism in the promoter region of the C-reactive protein gene associated with the plasma concentration of C-reactive protein. Atherosclerosis 2005, 178(1):193-198. 10.1016/j.atherosclerosis.2004.08.018, 15585218.
28. Suk HJ, Ridker PM, Cook NR, Zee RY. Relation of polymorphism within the C-reactive protein gene and plasma CRP levels. Atherosclerosis 2005, 178(1):139-145. 10.1016/j.atherosclerosis.2004.07.033, 15585211.
29. Szalai AJ, Wu J, Lange EM, McCrory MA, Langefeld CD, Williams A, Zakharkin SO, George V, Allison DB, Cooper GS, Xie F, Fan Z, Edberg JC, Kimberly RP. Single-nucleotide polymorphisms in the C-reactive protein (CRP) gene promoter that affect transcription factor binding, alter transcriptional activity, and associate with differences in baseline serum CRP level. J Mol Med 2005, 83(6):440-447. 10.1007/s00109-005-0658-0, 15778807.
30. Carlson CS, Aldred SF, Lee PK, Tracy RP, Schwartz SM, Rieder M, Liu K, Williams OD, Iribarren C, Lewis EC, Fornage M, Boerwinkle E, Gross M, Jaquish C, Nickerson DA, Myers RM, Siscovick DS, Reiner AP. Polymorphisms within the C-reactive protein (CRP) promoter region are associated with plasma CRP levels. Am J Hum Genet 2005, 77(1):64-77. 10.1086/431366, 1226195, 15897982.
31. Kathiresan S, Larson MG, Vasan RS, Guo CY, Gona P, Keaney JF, Wilson PW, Newton-Cheh C, Musone SL, Camargo AL, Drake JA, Levy D, O'Donnell CJ, Hirschhorn JN, Benjamin EJ. Contribution of clinical correlates and 13 C-reactive protein gene polymorphisms to interindividual variability in serum C-reactive protein level. Circulation 2006, 113(11):1415-1423. 10.1161/CIRCULATIONAHA.105.591271, 16534007.
32. Eklund C, Kivimaki M, Islam MS, Juonala M, Kahonen M, Marniemi J, Lehtimaki T, Viikari J, Raitakari OT, Hurme M. C-reactive protein genetics is associated with carotid artery compliance in men in The Cardiovascular Risk in Young Finns Study. Atherosclerosis 2008, 196(2):841-848. 10.1016/j.atherosclerosis.2007.01.027, 17350021.
33. Reiner AP, Barber MJ, Guan Y, Ridker PM, Lange LA, Chasman DI, Walston JD, Cooper GM, Jenny NS, Rieder MJ, Durda JP, Smith JD, Novembre J, Tracy RP, Rotter JI, Stephens M, Nickerson DA, Krauss RM. Polymorphisms of the HNF1A gene encoding hepatocyte nuclear factor-1 alpha are associated with C-reactive protein. Am J Hum Genet 2008, 82(5):1193-1201. 10.1016/j.ajhg.2008.03.017, 2427318, 18439552.
34. Ridker PM, Pare G, Parker A, Zee RY, Danik JS, Buring JE, Kwiatkowski D, Cook NR, Miletich JP, Chasman DI. Loci related to metabolic-syndrome pathways including LEPR, HNF1A, IL6R, and GCKR associate with plasma C-reactive protein: the Women's Genome Health Study. Am J Hum Genet 2008, 82(5):1185-1192. 10.1016/j.ajhg.2008.03.015, 2427311, 18439548.
35. Erdmann J, Grosshennig A, Braund PS, Konig IR, Hengstenberg C, Hall AS, Linsel-Nitschke P, Kathiresan S, Wright B, Tregouet DA, Cambien F, Bruse P, Aherrahrou Z, Wagner AK, Stark K, Schwartz SM, Salomaa V, Elosua R, Melander O, Voight BF, O'Donnell CJ, Peltonen L, Siscovick DS, Altshuler D, Merlini PA, Peyvandi F, Bernardinelli L, Ardissino D, Schillert A, Blankenberg S, et al. New susceptibility locus for coronary artery disease on chromosome 3q22.3. Nat Genet 2009,
36. Armendariz AD, Krauss RM. Hepatic nuclear factor 1-alpha: inflammation, genetics, and atherosclerosis. Curr Opin Lipidol 2009, 20(2):106-111. 10.1097/MOL.0b013e3283295ee9, 19280766.
37. Courtois G, Morgan JG, Campbell LA, Fourel G, Crabtree GR. Interaction of a liver-specific nuclear factor with the fibrinogen and alpha 1-antitrypsin promoters. Science 1987, 238(4827):688-692. 10.1126/science.3499668, 3499668.
38. Bell GI, Polonsky KS. Diabetes mellitus and genetically programmed defects in beta-cell function. Nature 2001, 414(6865):788-791. 10.1038/414788a, 11742410.
39. Koudritsky M, Domany E. Positional distribution of human transcription factor binding sites. Nucleic Acids Res 2008, 36(21):6795-6805. 10.1093/nar/gkn752, 2588498, 18953043.
40. Odom DT, Dowell RD, Jacobsen ES, Nekludova L, Rolfe PA, Danford TW, Gifford DK, Fraenkel E, Bell GI, Young RA. Core transcriptional regulatory circuitry in human hepatocytes. Mol Syst Biol 2006, 2:2006 0017. 10.1038/msb4100059, 1681491, 16738562.
41. Li SP, Goldman ND. Regulation of human C-reactive protein gene expression by two synergistic IL-6 responsive elements. Biochemistry 1996, 35(28):9060-9068. 10.1021/bi953033d, 8703909.
42. Winkelmann BR, Marz W, Boehm BO, Zotz R, Hager J, Hellstern P, Senges J. Rationale and design of the LURIC study--a resource for functional genomics, pharmacogenomics and long-term prognosis of cardiovascular disease. Pharmacogenomics 2001, 2(1 Suppl 1):S1-73. 10.1517/14622416.2.1.S1, 11258203.
43. Austen WG, Edwards JE, Frye RL, Gensini GG, Gott VL, Griffith LS, McGoon DC, Murphy ML, Roe BB. A reporting system on patients evaluated for coronary artery disease. Report of the Ad Hoc Committee for Grading of Coronary Artery Disease, Council on Cardiovascular Surgery, American Heart Association. Circulation 1975, 51(4 Suppl):5-40.
44. American Diabetes Association Diagnosis and classification of diabetes mellitus. Diabetes Care 2006, 29(Suppl 1):S43-48. American Diabetes Association.
45. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, Macfadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ. Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet 2009, 373(9670):1175-1182. 10.1016/S0140-6736(09)60447-5, 19329177.
46. Koenig W. Is hsCRP Back on Board? Implications from the JUPITER Trial. Clin Chem 2009, 55(2):216-218. 10.1373/clinchem.2008.115915, 19074517.
47. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, MacFadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008, 359(21):2195-2207. 10.1056/NEJMoa0807646, 18997196.
48. Marz W, Winkler K, Nauck M, Bohm BO, Winkelmann BR. Effects of statins on C-reactive protein and interleukin-6 (the Ludwigshafen Risk and Cardiovascular Health study). Am J Cardiol 2003, 92(3):305-308. 10.1016/S0002-9149(03)00633-7, 12888140.
49. Koenig W, Sund M, Frohlich M, Fischer HG, Lowel H, Doring A, Hutchinson WL, Pepys MB. C-Reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. Circulation 1999, 99(2):237-242.